08:17 AM EDT, 09/20/2024 (MT Newswires) -- Merck ( MRK ) said Friday that it has received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use for its anti-PD-1 therapy Keytruda in two gynecologic cancer indications.

The first opinion recommends Keytruda with carboplatin and paclitaxel as first-line treatment of advanced or recurrent endometrial carcinoma, while the second opinion endorses Keytruda with chemoradiotherapy for locally advanced cervical cancer, the company said.

The recommendations are based on two late-stage trials, the company said, adding that the European Commission's final decision is expected in Q4.

Price: 117.34, Change: +0.11, Percent Change: +0.09